Abstract. Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms, displaying variable morphological and clinicopathological features. Supportive immunohistochemical markers such as CD34, CD99, BCL2 and LSD1 are commonly applied in the differential diagnosis of SFTs, although none is sufficiently sensitive or specific enough. The aim of the present study was to examine the most differential markers for the reliable distinction of SFTs from histological mimics. We investigated the expression of STAT6, NAB2, ALDH1, GRIA2 and IGF2 in 454 comprehensive soft tissue tumors, comprising formalin-fixed paraffin-embedded (FFPE) tissue samples from 80 SFTs and 374 other mesenchymal tumors. The Duolink in situ proximity ligation assay (PLA) was adopted for the detection of NAB2-STAT6 fusion proteins. STAT6 was expressed in all 80 SFT cases with a moderate-strong nuclear staining intensity. In contrast, only 4/374 (1%) non-SFT mesenchymal tumors showed a nuclear STAT6 staining pattern. Strong expression of NAB2 and IGF2 was detected in SFT and non-SFT cases. Positive GRIA2 immunoreactivity was found in 64% (SFT) and 8% (non-SFT), respectively. Expression of ALDH1 was moderate-strong in 76% (SFT), whereas only 2 non-SFT lesions showed positive ALDH1 immunoreactivity. Moreover, the presence of NAB2-STAT6 fusion proteins was indicated in 71/78 (91%) SFT cases by PLA. Nuclear STAT6 and cytoplasmic ALDH1 expression are the most sensitive and specific markers in the differential diagnosis of SFTs. Furthermore, application of Duolink in situ proximity ligation assay can be helpful to detect the NAB2-STAT6 fusion protein in the majority of SFTs.
Introduction
Solitary fibrous tumor (SFT) is a mesenchymal tumor which can arise from any organ in the body with no gender preference (1) (2) (3) . According to the WHO classification (2013), SFTs are classified as tumors with intermediate malignancy and rarely metastatic potential (4) . Some characteristics of aggressiveness including tumor size >15 cm, age >55 years and mitotic index >4/10 high power fields (HPF) are shown to increase the risk of metastasis and mortality (5) . The most efficient treatment is complete resection of tumor bulk with adequate margins. To date, no adjuvant treatment strategy exists due to the resistance of tumor cells to chemo-and radiotherapy (6) (7) (8) .
Histologically, establishment of SFT diagnosis can be challenging as immunohistochemical markers such as CD34, BCL2 or CD99 are widely expressed in a variety of other soft tissue tumors and neither is sensitive nor specific enough. Furthermore, the more or less characteristic morphology with hyper-and hypocellular areas of fibroblast-like cells in a so-called pattern less architecture can occur in a large number of non-SFTs. This is also true for the so-called hemangiopericytoma-like vascular pattern which consists of plenty of branching vessels with a staghorn pattern (4) . Because of the existence of several tumor entities which may exhibit a 'hemangiopericytoma'-like architecture, the designation 'hemangiopericytoma' has now been deleted in the current WHO classification from 2013 (4) . Common diagnostic pitfalls of SFTs are other spindle cell lesions such as gastrointestinal stromal tumors, vascular neoplasia or dedifferentiated liposarcomas.
Recently, a recurrent cytogenetic alteration has been identified in the vast majority of SFTs, leading to the specific gene fusion of NAB2 and STAT6 (9, 10) . NAB2 is a transcriptional modulator of zinc finger transcription factors and located in Differential diagnosis of solitary fibrous tumors: A study of 454 soft tissue tumors indicating the diagnostic value of nuclear STAT6 relocation and ALDH1 expression combined with in situ proximity ligation assay the nucleus (11, 12) . STAT6 is involved in activation of transcription and in IL4-mediated biological responses. It is a cytoplasmic protein which can be phosphorylated by receptor associated kinases, resulting in relocation to the nucleus (13) . The NAB2-STAT6 gene fusion product leads to the enhanced expression of EGR1 (early growth response 1) targeted genes such as IGF2 (10) . Furthermore, GRIA2 has been reported as the top upregulated gene in a whole gene expression study of SFTs (14) . Another upregulated protein is ALDH1 which has been shown to be a potential diagnostic marker of meningeal SFTs and hemangiopericytoma (HPC) (15) . As correct diagnosis of SFTs is still challenging due to the lack of reliable tumor markers, in the present study we aimed at identifying diagnostically relevant markers, facilitating the differential diagnosis. We investigated the expression of STAT6, NAB2, ALDH1, GRIA2 and IGF2 by immunohistochemistry. In addition, we established the Duolink in situ proximity ligation assay (PLA) to identify the recurrent NAB2-STAT6 gene fusion product at protein level and explored the correlation between the presence of this specific gene fusion and the immunohistochemical positivity of nuclear STAT6 and NAB2.
Materials and methods
Retrieval of tumor samples. To constitute a comprehensive tumor collection, we retrospectively analyzed our archives at the Department of Pathology (Cologne) and the GIST and Sarcoma Registry (Cologne/Bonn, 19942012) for following diagnoses: solitary fibrous tumor (SFT) and hemangiopericytoma (HPC). We initially retrieved 106 formalin-fixed paraffin-embedded (FFPE) tumor samples. Due to the lack of remaining FFPE material, 8 samples had to be excluded from further analyses. According to the current WHO classification of tumors, all SFT diagnoses have been reviewed and re-evaluated by two experienced pathologist based on standard morphological criteria, immuno/histopathological and in selected cases, corroborative molecular procedures. In summary, 80 comprehensive SFT cases were included in the present study and 18 cases had to be excluded due to re-classification (35 women, 45 men; median age at diagnosis, 59.5 years; range, 21-92 years; median tumor size, 8 cm; range, 0.8-25 cm; summarized in Table I ). Overall, tissue samples were excisions from various anatomic locations including: abdomen (n=16), extremities (n=3), head and neck (n=10), lung (n=8), mesenterium (n=4), pelvis (n=8), pleura (n=19), prostate (n=6), retroperitoneum (n=2) and thorax (n=4). Individual clinicopathological characteristics are summarized in Table II . The study was approved by the local Ethics Committee and conducted in accordance with current ethical standards (Declaration of Helsinki, 1975) .
Tumor microarrays (TMAs).
To examine the specificity (SP) and sensitivity (SE) of various diagnostic markers, we used 12 different TMAs (each FFPE tumor tissue block with at least two representative 1-mm cores) constructed in our collaborative research group (Competence network for sarcomas, KoSar). Overall, 385 non-SFT mesenchymal tumors were represented: angiosarcomas (AS; n=29), dedifferentiated liposarcomas (DDLS; n=74), hemangiomas (n=6), leiomyosarcomas (LMS; n=70), malignant peripheral nerve sheath tumors (MPNST; n=24), myxoid liposarcomas (MLS; n=29), pleomorphic liposarcomas (PLS; n=11), schwannomas (n=12), synovial sarcomas (SS; n=16), undifferentiated pleomorphic sarcomas (UPS; n=36) and well-differentiated liposarcomas (WDLS; n=78). Selected tumor areas were confirmed by two experienced pathologists before and after TMA construction. GRIA2) followed by ii) incubation with respective primary antibodies (37˚C for 30 min) and iii) employment of the BrightVision+ histostaining detection system (Poly-HRP-anti Ms/Rb/Rt IgG, DPVB999HRP; ImmunoLogic, Duiven, The Netherlands) according to the manufacturer's instructions (RT, 15 min). Staining with CD34, CD99, BCL2 and LSD1 was performed on a routine diagnostic Leica Bond-Max IHC system (Leica Biosystems, Nussloch, Germany) using standard protocols. Cytoplasmic and nuclear immunoreactivity was scored combining: i) staining intensity (0, non-existent; 1, weak; 2, moderate; and 3, strong) and ii) staining proportion (0, no staining; 1, <1% positive cells; 2, 1-10% positive cells; 3, 11-33% positive cells; 4, 34-65% positive cells; and 5, ≥66% positive cells). Only cases with moderate to strong staining in >10% cells (proportion score >2) were considered positive for the purposes of the study.
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Duolink in situ proximity ligation assay (PLA).
Sections from FFPE blocks (4 µm) were processed according to the Duolink PLA manufacturer's brightfield instructions (Duo92012; Sigma-Aldrich, St. Louis, MO, USA). In brief: i) pretreatment using EDTA (pH 8.0) for 25 min at 100˚C, followed by ii) peroxidase quenching and blocking, incubation with iii) the identical primary NAB2 and STAT6 antibodies as used for immunohistochemistry (1:100 and 1:400 dilution, respectively) at 37˚C for 30 min; and iv) secondary antibodies (PLA probe PLUS and MINUS, conjugated with oligonucleotides); v) enzymatic ligation depending on the close proximity of the PLA probes PLUS and MINUS (37˚C for 30 min); vii) circle amplification (37˚C for 120 min); and viii) terminal detection and nuclear counterstaining. Evaluation of the processed slides was performed using a Leica DMLB brightfield microscope.
Results

STAT6, NAB2, ALDH1, GRIA2 and IGF2 immunohistochemistry.
Initially, SFT sections were stained with conventional immunohistochemical markers, indicating a non-specific SFT profile: CD34 was expressed in 70/80 (88%; Fig. 1C ), BCL2 in 57/80 (71%; Fig. 1G ), LSD1 in 71/80 (89%; Fig. 1H ) and CD99 in 33/80 (41%) SFT samples (Tables II and III (Fig. 3) . Restricted cytoplasmic STAT6 expression was heterogeneously intense and present across all tumor entities. Thus, nuclear positivity for STAT6 was found highly specific (SP) and sensitive (SE) for the diagnosis of SFT vs. other mesenchymal tumors (SP, 99%; PPV 95%; Table Iv) . We next analyzed the diagnostic value of NAB2 expression. A total of 80 out of 80 (100%) SFTs showed positive NAB2 staining (Figs. 1B and 2 ), compared to a considerable fraction of other mesenchymal soft tissue tumors: 14/29 (48%) angiosarcomas, 27/72 (38%) dedifferentiated liposarcomas, 4/6 (67%) hemangiomas, 14/68 (21%) leiomyosarcomas, 11/24 (46%) malignant peripheral nerve sheath tumors, 20/29 (69%) myxoid liposarcomas, 2/9 (22%) pleomorphic liposarcomas, 11/12 (92%) schwannomas, 7/15 (47%) synovial sarcomas, 13/35 (37%) undifferentiated pleomorphic sarcomas and 23/75 (31%) well-differentiated liposarcomas showed positive stainings for NAB2 (Table III) . In contrast to nuclear STAT6, no significant distinction in the differential diagnosis of SFTs was observed for the expression of NAB2 (SP, 61%; PPV 35%; Table Iv ). peripheral nerve sheath tumors, myxoid liposarcomas, pleomorphic liposarcomas, synovial sarcomas, undifferentiated pleomorphic sarcomas, rhabdomyosarcoma, myxofibrosarcoma and endometrial stromal sarcoma. Cytoplasmic ALDH1 expression was present in 25/33 (76%) SFT samples (Fig. 1D ) and also observed in one case of rhabdomyosarcoma and endometrial stromal sarcoma. Specificity and sensitivity for the diagnosis of SFT vs. other mesenchymal tumors was 96 and 76%, respectively (Table Iv) .
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GRIA2 expression was also investigated (individual SFT TMA and 374 other mesenchymal samples). A total of 21 out of 33 (64%) SFTs (Fig. 1E ), 1/29 (3%) angiosarcomas, 3/72 (4%) dedifferentiated liposarcomas, 0/6 (0%) hemangiomas, 22/68 (32%) leiomyosarcomas, 1/24 (4%) malignant peripheral nerve sheath tumors, 0/29 (0%) myxoid liposarcomas, 0/9 (0%) pleomorphic liposarcomas, 0/12 (0%) schwannomas, 3/15 (20%) synovial sarcomas, 0/35 (0%) undifferentiated pleomorphic sarcomas and 0/75 (0%) well-differentiated liposarcomas showed high levels of cytoplasmic GRIA2 (SP, 92%; SE, 64%; PPV, 41%; Table IV ).
In addition, IGF2 expression was examined in 407 soft tissue tumors comprising 33 SFT cases (individual SFT TMA) and 374 non-SFT mesenchymal neoplasms. Cytoplasmic IGF2 expression was observed in 25/33 (76%) SFTs (Fig. 1F) , 16/29 (55%) angiosarcomas, 27/72 (38%) dedifferentiated liposarcomas, 2/6 (33%) hemangiomas, 29/68 (43%) leiomyosarcomas, 7/24 (29%) malignant peripheral nerve sheath tumors, 3/29 (10%) myxoid liposarcomas, 3/9 (33%) pleomorphic liposarcomas, 1/12 (8%) schwannomas, 7/15 (47%) synovial sarcomas, 7/35 (20%) undifferentiated pleomorphic sarcomas and 40/75 (55%) well-differentiated liposarcomas (Table III) . No significant difference was noted comparing the SE (76%) and SP (62%) of IGF2 expression for the diagnosis of SFT (PPV, 15%; Table IV ). All individual SFT results are summarized in Table II .
Duolink proximity ligation assay (PLA) in SFTs.
Presence of the NAB2-STAT6 fusion protein was indicated based on the Duolink in situ proximity ligation brightfield assay and supported by nuclear STAT6-NAB2 IHC stainings. Positive signals were observed in 71/78 (91%) SFT cases (two cases failed to be processed due to the lack of remaining FFPE material), providing highly suggestive evidence for the proximate co-localization of STAT6 and NAB2 antigens within a distance of ~30 nm (Fig. 4A) . In contrast to positive STAT6 and NAB2 nuclear immunoreactivity, no evidence for the pres- ence of NAB2-STAT6 fusion proteins was recognized in 7/78 (9%) SFT cases. The concordance of nuclear STAT6/NAB2 IHC staining results and the Duolink in situ proximity ligation assay is summarized in Fig. 4B and indicated in Figs. 2 and 5 .
Expression of STAT6, ALDH1 and GRIA2 in different tumor derived cell lines. Expression levels of STAT6, ALDH1 and GRIA2 were additionally examined in total protein extracts from primary SFT tumor tissues and non-SFT-derived cell lines by immunoblotting (Fig. 6) . Total STAT6 expression was heterogeneously intense and observed across all cell lines (with only limited levels of total STAT6 in gastrointestinal stromal tumors). In contrast, GRIA2 and ALDH1 expression was mainly detectable in two primary SFT tumor tissue samples and singularly in one GIST derived cell line (GIST48).
Discussion
Solitary fibrous tumor is a mesenchymal neoplasm which can arise from any organ in the body (2) . Aggressive behavior has been reported in up to 10% of SFT cases depending on tumor location, size and mitotic activity (4,16,17 ). Presenting as a painless mass is the main manifestation of this tumor, however, some patients suffer from hypoglycemia as a paraneoplastic syndrome the so-called Doege-Potter syndrome. Besides standard H&E morphology, CD34, CD99, BCL2 and LSD1 are supportive immunohistochemistry markers which can help to diagnose this tumor but are of low specificity (4, 18) . As the histomorphological spectrum of SFT is wide, the list of possible diagnostic pitfalls is long. Until recently, the genomic background of SFT was poorly understood and reliable specific immunohistochemical markers were missing. Recent findings showed the fusion of NAB2 and STAT6 on chromosome 12 in the majority of SFT. Robinson et al (10) reported NAB2-STAT6 gene fusions in 51/51 (100%) SFT cases using whole exome sequencing. This fusion has also been found using transcriptome sequencing in 29/53 (54.7%) SFT cases by Chmielecki et al (9) . RT-PCR showed NAB2-STAT6 fusions in 37/41 (90.2%) cases of SFT in another study (14) . It has been shown that there are various breakpoints in the NAB2 and STAT6 gene. Breaking in the STAT6 gene occurs within, or in the N-terminal to the Src homology domain. Thus, the transcriptional activator domain will be preserved in the fused state. Since NAB2 exchanges its repressor domain with the transcriptional activator of STAT6 and its breakpoint (Table II) . Incomplete concordance between IHC and Duolink in situ PLA results was observed for 7 cases (9%). Due to lack of remaining FFPE material, 2 cases could not be determined.
is C-terminal to the nuclear localization signal, the obtained fused protein has a nuclear localization possessing a transcriptional activity (19) .
Schweizer et al (19) We observed nuclear STAT6 expression in all 80 SFT cases and additional cytoplasmic STAT6 expression in 8 tumors which is in line with previous findings. Notably, we observed nuclear STAT6 expression in 4 non-SFT mesenchymal tumors comprising: well-differentiated liposarcomas (2/75), dedifferentiated liposarcoma (1/72) and synovial sarcoma (1/15). The observation of nuclear STAT6 expression in liposarcomas was first described by Doyle et al (20) with 3/4 non-SFT STAT6 nuclear-positive samples belonging to the group of dedifferentiated liposarcomas. Shortly thereafter, STAT6 amplification (STAT6 gene is located on chromosome 12 adjacent to MDM2 and CDK4) was demonstrated in a subset of liposarcomas, suggestively explaining why a subgroup of liposarcomas may express high levels of nuclear STAT6 (23) . However, the role of STAT6 in these liposarcomas and its potential transcriptional activity has to be clarified in further studies. As dedifferentiated liposarcomas may also express CD34 and may present with a hemangiopericytoma-like growth pattern, detection of MDM2 amplification helps to identify dedifferentiated liposarcomas from SFTs.
In the present study, NAB2 was expressed at high levels in all SFT cases and also in a large number of non-SFT soft tissue tumors. We conclude that this marker lacks specificity as additional diagnostic marker. To evaluate the relevance of potential target genes of the NAB2-STAT6 fusion protein, we further evaluated IGF2 expression. Robinson et al (10) have indicated that the NAB2-STAT6 fusion protein can induce expression of EGR1 targeted genes (e.g. IGF2). Furthermore, they showed expression of IGF2 also in an SFT cell line expressing the chimeric NAB2-STAT6 fusion protein. We detected expression of IGF2 in 25/33 SFT cases and 142/374 evaluated mesenchymal tumors. Besides, Steigen et al (24) showed SFT to express the highest level of IGF2 (80%) among their evaluated panel of mesenchymal tumors including MPNST (50%), SS (40%), MLS (40%) and UPS (30%). Notably, IGF2-induced hypoglycemia has been observed not only in SFTs but also in other mesenchymal tumors such as fibrosarcoma/fibroma (23%) and mesothelioma (8%) (25) . For diagnostic purpose, IGF2 expression is not specific enough to support diagnosis of SFT.
In several recent studies, GRIA2 has been shown to be upregulated in SFT samples (14, 26) . We detected expression of GRIA2 in 64% of SFT cases, which is comparable to the study by vivero et al (27) . We also found GRIA2 to be expressed in other mesenchymal tumors such as leiomyosarcomas (22/68), synovial sarcomas (3/15), angiosarcomas (1/29) and malignant peripheral nerve sheath tumors (1/24). GRIA2 specificity and sensitivity for the diagnosis of SFTs versus other mesenchymal tumors was 92% and 64%, respectively. Unlike the study of vivero et al (27) which showed dedifferentiated liposarcoma not to express GRIA2, we have detected GRIA2 expression in 3/72 (4.2%) dedifferentiated liposarcomas.
In the present study, ALDH1 expression was detected in 76% of SFTs. This finding is similar to a study conducted by Bouvier et al (15) . Additionally, they reported positive ALDH1 stainings in 2/163 cases of meningioma and 7/98 cases of synovial sarcoma which should be distinguished from solitary fibrous tumors of the meninges. As only 2/44 non-SFT cases showed expression of ALDH1, detection of ALDH1 may be of diagnostic help in SFT (SE, 76%; SP, 96%; PPV, 93% and NPV, 84%). Taken together, on the immunohistochemical level, ALDH1 could be introduced as both relatively sensitive and specific markers for SFT, whereas NAB2 and IGF2 are expressed in a large number of different non-SFT and conclusively not specific enough. In summary, nuclear expression of STAT6 is the most specific diagnostic immunohistochemical marker of SFT.
Overall, the Duolink proximity ligation assay is a useful molecular technique for the detection of NAB2-STAT6 fusion proteins, with the vast majority of SFT cases (71/78 cases; 91%) shown to be positive for the proximate co-localization of STAT6 and NAB2 antigens. However, 7 SFT cases without positive PLA signals indicate: i) that a subgroup of SFT will be under-diagnosed due to the negative reaction; and ii) this observation points to the possibility that not all SFTs which were clearly diagnosed by immunohistochemical markers carry the specific NAB2-STAT6 translocation subtypes. One explanation might be that the specific antigens may be truncated due to a different translocation subtype (28) . Additionally, it cannot be ruled out that a subgroup of SFT may harbor other translocation types than those described until now.
In summary, we propose the following algorithm to establish a reliable diagnosis of SFTs: i) standard H&E morphology with variable cellularity and high vascularity including the so-called staghorn thick wall vessels, combined with ii) immunohistochemistry for the detection of nuclear STAT6 (validated as the most specific and highly sensitive marker for SFTs), ALDH1 and CD34 positivity. As several NAB2-STAT6 translocation subtypes have been identified so far, further detailed evaluations concerning the prognostic and therapeutic impact have to be conducted. In this context, additional molecular analyses such as RT-PCR and/or Duolink in situ proximity ligation assays could further help to complement the diagnosis of SFTs. An established FISH assay is not available and with respect to routine clinical care, immunohistochemistry is superior to in situ proximity ligation assays to be applied in various pathology departments.
